Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Prothena Corporation News

    20,54 $ -0,10% -0,02 $
    In : 19,213 € | 17:17:30 Uhr Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A1KAVV
    ISIN: IE00B91XRN20
    US-Symbol: PRTA
    Typ: Aktie

    Prothena Corporation News

    15.03.23 - PR Newswire
    Biotech Sector Working Fast to Combat Alzheimer's Disease Cases That are Set to Explode
    Biotech Sector Working Fast to Combat Alzheimer's Disease Cases That are Set to Explode PR Newswire
    27.10.22 - GlobeNewswire
    Prothena to Report Third Quarter 2022 Financial Results on November 3rd
    DUBLIN, Ireland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
    28.09.22 - PR Newswire
    Thinking about buying stock in Acumen Pharmaceuticals, Prothena Corp, Anavex Life Sciences, Ocugen, or OraSure Technologies?
    Thinking about buying stock in Acumen Pharmaceuticals, Prothena Corp, Anavex Life Sciences, Ocugen, or OraSure Technologies? PR Newswire
    01.09.22 - GlobeNewswire
    Prothena to Participate in Upcoming Healthcare Conferences
    DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
    01.09.22 - GlobeNewswire
    Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors
    DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
    08.08.22 - GlobeNewswire
    Prothena Reports Second Quarter 2022 Financial Results and Business Highlights
    Net cash used in operating and investing activities was $35.5 million in the second quarter and $72.9 million for the first six months of 2022; quarter-​end cash and restricted cash ...
    02.08.22 - GlobeNewswire
    Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of novel ...
    01.08.22 - GlobeNewswire
    Prothena to Report Second Quarter 2022 Financial Results on August 8th
    DUBLIN, Ireland, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
    01.07.22 - GlobeNewswire
    Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    DUBLIN, Ireland, July 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of novel ...
    02.06.22 - GlobeNewswire
    Prothena to Participate in Jefferies Healthcare Conference
    DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
    05.05.22 - GlobeNewswire
    Prothena Reports First Quarter 2022 Financial Results and Business Highlights
    Net cash used in operating and investing activities was $37.4 million in the first quarter; quarter-​end cash and restricted cash position was $544.3 million Advanced PRX012, a ...
    28.04.22 - GlobeNewswire
    Prothena to Report First Quarter 2022 Financial Results on May 5th
    DUBLIN, Ireland, April 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
    26.04.22 - GlobeNewswire
    Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
    PRX012 is a potential best-​in-class, subcutaneous anti-​amyloid beta antibody therapy currently in a Phase 1 clinical study for the treatment of Alzheimer’s disease DUBLIN, Ireland, ...
    28.03.22 - GlobeNewswire
    Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
    Prothena has initiated Phase 1 SAD study of PRX012, under investigation for the treatment of Alzheimer’s disease DUBLIN, Ireland, March 28, 2022 (GLOBE NEWSWIRE) -- ...
    21.03.22 - GlobeNewswire
    Prothena to Participate in Stifel 2022 Virtual CNS Days
    DUBLIN, Ireland, March 21, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
    16.03.22 - GlobeNewswire
    Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022
    Oral presentation on preclinical data demonstrates Prothena’s dual Aβ/tau vaccine, for the potential treatment and prevention of Alzheimer’s, generated anti-Aβ and anti-tau antibodies to ...
    17.02.22 - GlobeNewswire
    Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights
    Net cash used in operating and investing activities was $22.8 million in the fourth quarter and net cash provided by operating and investing activities was $92.0 million for the full ...
    10.02.22 - GlobeNewswire
    Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022
    DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
    29.11.21 - GlobeNewswire
    Prothena to Participate in JMP Securities Hematology and Oncology Summit
    DUBLIN, Ireland, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-​stage clinical biotechnology company with a robust pipeline of ...
    04.11.21 - GlobeNewswire
    Prothena Reports Third Quarter 2021 Financial Results and Business Highlights
    Net cash provided by operating and investing activities was $111.9 million in the third quarter and $114.8 million for the first nine months of 2021; Quarter-​end cash and restricted ...

    Newssuche

    Videos

    newspaper
    08:50 Uhr
    Technical Trading: AUD/USD mit Mega Chance
    AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »